| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A clinical review of bleeding dilemmas in trauma
|
Hoyt, David B
|
|
2004
|
|
S1 |
p. 40-43
4 p.
|
artikel
|
| 2 |
Acquired Hemophilia
|
Collins, Peter
|
|
2006
|
|
S1 |
p. S90-
1 p.
|
artikel
|
| 3 |
Acquired von Willebrand Syndrome: An Underdiagnosed and Misdiagnosed Bleeding Complication in Patients With Lymphoproliferative and Myeloproliferative Disorders
|
Federici, Augusto B.
|
|
2006
|
|
S1 |
p. S48-S58
11 p.
|
artikel
|
| 4 |
Advances in Gene Therapy Using Factor VIIa in Hemophilia
|
Margaritis, Paris
|
|
2006
|
|
S1 |
p. S101-S104
4 p.
|
artikel
|
| 5 |
Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?
|
Yacobovich, Joanne
|
|
2016
|
|
S1 |
p. S64-S66
3 p.
|
artikel
|
| 6 |
A Prospective, Observational, Post-approval Registry of Inhibitor Patients Treated With Multiple or Single Doses of Recombinant Activated Factor VII
|
Chambost, Hervé
|
|
2008
|
|
S1 |
p. S35-S37
3 p.
|
artikel
|
| 7 |
Arthropathy in Inhibitor Patients: Differences in the Joint Status
|
Hoots, W. Keith
|
|
2008
|
|
S1 |
p. S42-S49
8 p.
|
artikel
|
| 8 |
Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives
|
Farrugia, Albert
|
|
2006
|
|
S1 |
p. S64-S69
6 p.
|
artikel
|
| 9 |
Autoimmunity and Novel Therapies in Immune-Mediated Thrombocytopenia
|
Yehudai, Dana
|
|
2013
|
|
S1 |
p. S100-S108
9 p.
|
artikel
|
| 10 |
B-Cell Depletion in Immune Thrombocytopenia
|
Godeau, Bertrand
|
|
2013
|
|
S1 |
p. S75-S82
8 p.
|
artikel
|
| 11 |
Bendamustine: Rescue of an Effective Antineoplastic Agent From the Mid-Twentieth Century
|
Leoni, Lorenzo M.
|
|
2011
|
|
S1 |
p. S4-S11
8 p.
|
artikel
|
| 12 |
Bendamustine's Emerging Role in the Management of Lymphoid Malignancies
|
Rummel, Mathias J.
|
|
2011
|
|
S1 |
p. S24-S36
13 p.
|
artikel
|
| 13 |
Bleeding complications after hematopoietic stem cell transplantation
|
Pihusch, Markus
|
|
2004
|
|
S1 |
p. 93-100
8 p.
|
artikel
|
| 14 |
Blood-Induced Joint Disease: The Confluence of Dysregulated Oncogenes, Inflammatory Signals, and Angiogenic Cues
|
Valentino, Leonard A.
|
|
2008
|
|
S1 |
p. S50-S57
8 p.
|
artikel
|
| 15 |
CD4+CD25+Foxp3+ Regulatory T Cells in the Pathophysiology of Immune Thrombocytopenia
|
Nishimoto, Tetsuya
|
|
2013
|
|
S1 |
p. S43-S49
7 p.
|
artikel
|
| 16 |
Celiac disease with Evans syndrome and isolated immune thrombocytopenia in monozygotic twins: a rare association
|
Roganovic, Jelena
|
|
2016
|
|
S1 |
p. S61-S63
3 p.
|
artikel
|
| 17 |
Cell Death in Immune Thrombocytopenia: Novel Insights and Perspectives
|
von Gunten, Stephan
|
|
2013
|
|
S1 |
p. S109-S115
7 p.
|
artikel
|
| 18 |
Challenges for providing effective hemostasis in surgery and trauma
|
Lawson, Jeffrey H
|
|
2004
|
|
S1 |
p. 55-64
10 p.
|
artikel
|
| 19 |
Childhood Immune Thrombocytopenia—Who Will Spontaneously Recover?
|
Yacobovich, Joanne
|
|
2013
|
|
S1 |
p. S71-S74
4 p.
|
artikel
|
| 20 |
Chronic Immune Thrombocytopenia in Children: Who Needs Splenectomy?
|
Schifferli, Alexandra
|
|
2013
|
|
S1 |
p. S58-S62
5 p.
|
artikel
|
| 21 |
Clinical Trials for Human T-Cell Lymphotropic Virus Type I–Associated Peripheral T-Cell Lymphoma in Japan
|
Tobinai, Kensei
|
|
2010
|
|
S1 |
p. S5-S7
3 p.
|
artikel
|
| 22 |
CME
|
|
|
2012
|
|
S1 |
p. A3-A4
nvt p.
|
artikel
|
| 23 |
Commentary on Session: Immune Thrombocytopenia Nomenclature, Guidelines, and Natural History
|
Bolton-Maggs, Paula H.B.
|
|
2013
|
|
S1 |
p. S10-S11
2 p.
|
artikel
|
| 24 |
Conclusion and Future Directions
|
Leoni, Lorenzo M.
|
|
2011
|
|
S1 |
p. S37-S38
2 p.
|
artikel
|
| 25 |
Congenital and Acquired Platelet Disorders: Current Dilemmas and Treatment Strategies
|
White II, Gilbert C.
|
|
2006
|
|
S1 |
p. S37-S41
5 p.
|
artikel
|
| 26 |
Consensus document for transfusion-related iron overload
|
Vichinsky, Elliott
|
|
2001
|
|
S1 |
p. 2-4
3 p.
|
artikel
|
| 27 |
Controversies and Challenges in Elective Orthopedic Surgery in Patients With Hemophilia and Inhibitors
|
Jiménez-Yuste, Victor
|
|
2008
|
|
S1 |
p. S64-S67
4 p.
|
artikel
|
| 28 |
Cover
|
|
|
2012
|
|
S1 |
p. OFC-
1 p.
|
artikel
|
| 29 |
Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications
|
Kessler, Craig M
|
|
2004
|
|
S1 |
p. 44-50
7 p.
|
artikel
|
| 30 |
Current issues with blood transfusions in sickle cell disease
|
Vichinsky, Elliott P
|
|
2001
|
|
S1 |
p. 14-22
9 p.
|
artikel
|
| 31 |
Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases
|
Sadik, Christian D.
|
|
2016
|
|
S1 |
p. S51-S53
3 p.
|
artikel
|
| 32 |
Deferoxamine pharmacokinetics
|
Porter, John B
|
|
2001
|
|
S1 |
p. 63-68
6 p.
|
artikel
|
| 33 |
Diagnosis of the myeloproliferative disorders: Resolving phenotypic mimicry
|
Spivak, Jerry L.
|
|
2003
|
|
S1 |
p. 1-5
5 p.
|
artikel
|
| 34 |
Disclaimer
|
Fruchtman, Steven M.
|
|
2003
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 35 |
Disclaimer
|
|
|
2012
|
|
S1 |
p. A2-
1 p.
|
artikel
|
| 36 |
DNA Methylation and Primary Immune Thrombocytopenia
|
Li, Huiyuan
|
|
2013
|
|
S1 |
p. S116-S126
11 p.
|
artikel
|
| 37 |
Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing
|
Abshire, Thomas C
|
|
2004
|
|
S1 |
p. 3-7
5 p.
|
artikel
|
| 38 |
Dosing with recombinant factor viia based on current evidence
|
Hedner, Ulla
|
|
2004
|
|
S1 |
p. 35-39
5 p.
|
artikel
|
| 39 |
Dynamics of Thrombus Formation
|
Furie, Bruce
|
|
2006
|
|
S1 |
p. S121-
1 p.
|
artikel
|
| 40 |
Early predictors of outcome in trauma patients
|
Lynn, Mauricio
|
|
2004
|
|
S1 |
p. 175-
1 p.
|
artikel
|
| 41 |
Editorial Board
|
|
|
2000
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 42 |
Elective orthopedic surgery for hemophilia patients with inhibitors: new opportunities
|
Rodriguez-Merchan, E.Carlos
|
|
2004
|
|
S1 |
p. 109-116
8 p.
|
artikel
|
| 43 |
Emerging risks and outcomes of blood transfusion in surgery
|
Shander, Aryeh
|
|
2004
|
|
S1 |
p. 117-124
8 p.
|
artikel
|
| 44 |
Enhancing Existing Approaches to Peripheral T-Cell Lymphoma
|
Foss, Francine M.
|
|
2010
|
|
S1 |
p. S8-S10
3 p.
|
artikel
|
| 45 |
Environmental and genetic factors influencing inhibitor development 1 1 Portions of this work have been previously published in Rodriquez-Merchan C, Goddard N, Lee C: Musculoskeletal Aspects of Haemophilia. Blackwell Science Publishing, 2000.
|
Oldenburg, Johannes
|
|
2004
|
|
S1 |
p. 82-88
7 p.
|
artikel
|
| 46 |
Epidemiological basis for future improvements in trauma care
|
Champion, Howard R.
|
|
2004
|
|
S1 |
p. 173-
1 p.
|
artikel
|
| 47 |
Etiology of the myeloproliferative disorders: The role of thrombopoietin
|
Kaushansky, Kenneth
|
|
2003
|
|
S1 |
p. 6-9
4 p.
|
artikel
|
| 48 |
Excluded abstracts
|
|
|
2004
|
|
S1 |
p. 176-
1 p.
|
artikel
|
| 49 |
Experiences with recombinant human factor VIIa in patients with thrombocytopenia
|
Goodnough, Lawrence Tim
|
|
2004
|
|
S1 |
p. 25-29
5 p.
|
artikel
|
| 50 |
Factor VIIa Interaction With Tissue Factor and Endothelial Cell Protein C Receptor on Cell Surfaces
|
Pendurthi, Usha R.
|
|
2008
|
|
S1 |
p. S21-S24
4 p.
|
artikel
|
| 51 |
Factor XI deficiency
|
O’Connell, Niamh M
|
|
2004
|
|
S1 |
p. 76-81
6 p.
|
artikel
|
| 52 |
Faculty Disclosure
|
|
|
2011
|
|
S1 |
p. A3-
1 p.
|
artikel
|
| 53 |
From immune substitution to immunomodulation
|
Wahn, Volker
|
|
2016
|
|
S1 |
p. S7-S9
3 p.
|
artikel
|
| 54 |
Functional Assessment of Arthropathy—An International Perspective
|
Poonnoose, Pradeep M.
|
|
2006
|
|
S1 |
p. S27-S32
6 p.
|
artikel
|
| 55 |
Functional Classification of Peripheral T-Cell Lymphomas as an Approach to Improve Outcome Prediction and Therapy Selection
|
Jones, Dan
|
|
2010
|
|
S1 |
p. S1-S4
4 p.
|
artikel
|
| 56 |
Further Understanding of Recombinant Activated Factor VII Mode of Action
|
Monroe, Dougald M.
|
|
2008
|
|
S1 |
p. S7-S11
5 p.
|
artikel
|
| 57 |
Glanzmann’s Thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII and Other Hemostatic Agents
|
Poon, Man-Chiu
|
|
2006
|
|
S1 |
p. S33-S36
4 p.
|
artikel
|
| 58 |
Hemostasis in liver resection surgery
|
Lodge, J.Peter A
|
|
2004
|
|
S1 |
p. 70-75
6 p.
|
artikel
|
| 59 |
High-Dose Recombinant Factor VIIa Therapy in Hemophilia Patients With Inhibitors
|
Kenet, Gili
|
|
2006
|
|
S1 |
p. S108-S110
3 p.
|
artikel
|
| 60 |
High-Dose Therapy and Stem Cell Transplantation
|
Zinzani, Pier Luigi
|
|
2010
|
|
S1 |
p. S15-S17
3 p.
|
artikel
|
| 61 |
Imbalanced immune homeostasis in immune thrombocytopenia
|
Yazdanbakhsh, Karina
|
|
2016
|
|
S1 |
p. S16-S19
4 p.
|
artikel
|
| 62 |
Immune Dysregulation in Immune Thrombocytopenia
|
Yazdanbakhsh, Karina
|
|
2013
|
|
S1 |
p. S63-S67
5 p.
|
artikel
|
| 63 |
Immune modulation for autoimmune disorders: evolution of therapeutics
|
Liebman, Howard A.
|
|
2016
|
|
S1 |
p. S23-S26
4 p.
|
artikel
|
| 64 |
Immune Thrombocytopenia and B-Cell-Activating Factor/A Proliferation-Inducing Ligand
|
Liu, Xin-guang
|
|
2013
|
|
S1 |
p. S89-S99
11 p.
|
artikel
|
| 65 |
Immune Thrombocytopenia Nomenclature, Consensus Reports, and Guidelines: What Are the Consequences for Daily Practice and Clinical Research?
|
Michel, Marc
|
|
2013
|
|
S1 |
p. S50-S54
5 p.
|
artikel
|
| 66 |
Immune Thrombocytopenia Patients Requiring Anticoagulation—Maneuvering Between Scylla and Charybdis
|
Matzdorff, Axel
|
|
2013
|
|
S1 |
p. S83-S88
6 p.
|
artikel
|
| 67 |
Immunological treatment of multiple sclerosis
|
Diebold, Martin
|
|
2016
|
|
S1 |
p. S54-S57
4 p.
|
artikel
|
| 68 |
Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlook
|
Godeau, Bertrand
|
|
2016
|
|
S1 |
p. S39-S42
4 p.
|
artikel
|
| 69 |
Immunomodulation of immunothrombocytopenia
|
Nimmerjahn, Falk
|
|
2016
|
|
S1 |
p. S10-S12
3 p.
|
artikel
|
| 70 |
Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumtic drugs
|
Walker, Ulrich A.
|
|
2016
|
|
S1 |
p. S58-S60
3 p.
|
artikel
|
| 71 |
Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors
|
d’Oiron, Roseline
|
|
2006
|
|
S1 |
p. S3-S9
7 p.
|
artikel
|
| 72 |
Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy
|
Treadwell, Marsha J
|
|
2001
|
|
S1 |
p. 77-84
8 p.
|
artikel
|
| 73 |
Indications for lowering platelet numbers in essential thrombocythemia
|
Barbui, Tiziano
|
|
2003
|
|
S1 |
p. 22-25
4 p.
|
artikel
|
| 74 |
Indications for red cell transfusion in sickle cell disease
|
Ohene-Frempong, Kwaku
|
|
2001
|
|
S1 |
p. 5-13
9 p.
|
artikel
|
| 75 |
Individualized Treatment for Immune Thrombocytopenia: Predicting Bleeding Risk
|
Neunert, Cindy E.
|
|
2013
|
|
S1 |
p. S55-S57
3 p.
|
artikel
|
| 76 |
Inhibitors to Factor XI in Patients With Severe Factor XI Deficiency
|
Salomon, Ophira
|
|
2006
|
|
S1 |
p. S10-S12
3 p.
|
artikel
|
| 77 |
Innate and Adaptive Immunity in Immune Thrombocytopenia
|
Lazarus, Alan H.
|
|
2013
|
|
S1 |
p. S68-S70
3 p.
|
artikel
|
| 78 |
Integrating the New Generation of Targeted Therapies for Chronic Myelogenous Leukemia
|
|
|
2007
|
|
S1 |
p. 33-34
2 p.
|
artikel
|
| 79 |
Intensive Exposure to Factor VIII May Be a Risk Factor for Inhibitor Development in Mild Hemophilia A
|
Manuel D., Carcao
|
|
2006
|
|
S1 |
p. S89-
1 p.
|
artikel
|
| 80 |
Introduction
|
White II, Gilbert C.
|
|
2006
|
|
S1 |
p. S1-S2
2 p.
|
artikel
|
| 81 |
Introduction
|
Jabbour, Elias
|
|
2007
|
|
S1 |
p. 1-3
3 p.
|
artikel
|
| 82 |
Introduction
|
Roberts, Harold R.
|
|
2004
|
|
S1 |
p. 1-2
2 p.
|
artikel
|
| 83 |
Introduction: Proceedings From the 9th Novo Nordisk Symposium on Haemostasis Management
|
Rodriguez-Merchan, E. Carlos
|
|
2008
|
|
S1 |
p. S1-S2
2 p.
|
artikel
|
| 84 |
Investing in Hemophilia Care: Benefits and Costs for Patients and Society
|
Scalone, Luciana
|
|
2008
|
|
S1 |
p. S31-S34
4 p.
|
artikel
|
| 85 |
Iron chelation: New therapies
|
Galanello, Renzo
|
|
2001
|
|
S1 |
p. 73-76
4 p.
|
artikel
|
| 86 |
Iron chelation therapy in sickle cell disease
|
Cohen, Alan R
|
|
2001
|
|
S1 |
p. 69-72
4 p.
|
artikel
|
| 87 |
Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease
|
Ballas, Samir K
|
|
2001
|
|
S1 |
p. 30-36
7 p.
|
artikel
|
| 88 |
Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura
|
Bell Jr, William R
|
|
2000
|
|
S1 |
p. 22-25
4 p.
|
artikel
|
| 89 |
Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients
|
Sipurzynski, J.
|
|
2016
|
|
S1 |
p. S43-S47
5 p.
|
artikel
|
| 90 |
Management of gastrointestinal bleeding in patients with cirrhosis of the liver
|
Bosch, Jaime
|
|
2004
|
|
S1 |
p. 8-12
5 p.
|
artikel
|
| 91 |
Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
|
Jakubowiak, Andrzej
|
|
2012
|
|
S1 |
p. S16-S32
17 p.
|
artikel
|
| 92 |
Massive Transfusion Coagulopathy
|
Levy, Jerrold H.
|
|
2006
|
|
S1 |
p. S59-S63
5 p.
|
artikel
|
| 93 |
Masthead
|
|
|
2006
|
|
S1 |
p. CO2-
1 p.
|
artikel
|
| 94 |
Masthead
|
|
|
2007
|
|
S1 |
p. CO2-
1 p.
|
artikel
|
| 95 |
Masthead
|
|
|
2012
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 96 |
Masthead
|
|
|
2011
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 97 |
Mechanism of Action of Recombinant Activated Factor VII: An Update
|
Hedner, Ulla
|
|
2006
|
|
S1 |
p. S105-S107
3 p.
|
artikel
|
| 98 |
Mechanism of Action: The Unique Pattern of Bendamustine-Induced Cytotoxicity
|
Leoni, Lorenzo M.
|
|
2011
|
|
S1 |
p. S12-S23
12 p.
|
artikel
|
| 99 |
Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for FcγRIIB falls by the wayside
|
Crow, Andrew R.
|
|
2016
|
|
S1 |
p. S20-S22
3 p.
|
artikel
|
| 100 |
Milestones in Hemophilia and Concepts in Future Clinical Trial Design
|
Lusher, Jeanne M.
|
|
2006
|
|
S1 |
p. S84-S87
4 p.
|
artikel
|
| 101 |
Modern treatment strategies in polycythemia vera
|
Gilbert, Harriet S.
|
|
2003
|
|
S1 |
p. 26-29
4 p.
|
artikel
|
| 102 |
Monitoring coagulation and the clinical effects of recombinant factor VIIa
|
Gabriel, Don A
|
|
2004
|
|
S1 |
p. 20-24
5 p.
|
artikel
|
| 103 |
Monitoring Inhibitor Patients With the Right Assays
|
Barrowcliffe, Trevor W.
|
|
2008
|
|
S1 |
p. S25-S30
6 p.
|
artikel
|
| 104 |
New alternatives for control of severe cardiac surgical bleeding
|
Gill, Ravi
|
|
2004
|
|
S1 |
p. 174-
1 p.
|
artikel
|
| 105 |
New Anti-thrombotic Agents: Emphasis on Hemorrhagic Complications and Their Management
|
Ng, Heng Joo
|
|
2006
|
|
S1 |
p. S77-S83
7 p.
|
artikel
|
| 106 |
New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)
|
Bouma, Bonno N
|
|
2004
|
|
S1 |
p. 13-19
7 p.
|
artikel
|
| 107 |
New Targeted Therapies for Chronic Myelogenous Leukemia: Opportunities to Overcome Imatinib Resistance
|
Jabbour, Elias
|
|
2007
|
|
S1 |
p. 25-31
7 p.
|
artikel
|
| 108 |
Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease
|
Brittenham, Gary M
|
|
2001
|
|
S1 |
p. 37-56
20 p.
|
artikel
|
| 109 |
Novel Agents in Development for Peripheral T-Cell Lymphoma
|
O'Connor, Owen A.
|
|
2010
|
|
S1 |
p. S11-S14
4 p.
|
artikel
|
| 110 |
Novel hemostatic alternatives in reconstructive surgery
|
Waner, Milton
|
|
2004
|
|
S1 |
p. 163-167
5 p.
|
artikel
|
| 111 |
Novel Therapies for Relapsed/Refractory Multiple Myeloma: How Can We Improve on “Salvage” Therapy?—Introduction
|
Jakubowiak, Andrzej
|
|
2012
|
|
S1 |
p. S1-S2
2 p.
|
artikel
|
| 112 |
Occult Hemorrhage in Immune Thrombocytopenia
|
Flores, Adolfo
|
|
2013
|
|
S1 |
p. S26-S30
5 p.
|
artikel
|
| 113 |
On-Label Versus Off-Label Use of Recombinant Activated Factor VII: A Comprehensive Review of Use in Two Canadian Centers
|
Carcao, Manuel D.
|
|
2008
|
|
S1 |
p. S68-S71
4 p.
|
artikel
|
| 114 |
Orthopedic Management in Hemophilia: A Spanish Outlook
|
Rodriguez-Merchan, E. Carlos
|
|
2008
|
|
S1 |
p. S58-S63
6 p.
|
artikel
|
| 115 |
Outside Front Cover
|
|
|
2016
|
|
S1 |
p. OFC-
1 p.
|
artikel
|
| 116 |
outside front cover, PMS 8883 metallic AND 4/C
|
|
|
2013
|
|
S1 |
p. OFC-
1 p.
|
artikel
|
| 117 |
Pathogenesis of Hemophilic Arthropathy
|
Hoots, W. Keith
|
|
2006
|
|
S1 |
p. S18-S22
5 p.
|
artikel
|
| 118 |
Peripheral T-Cell Lymphomas: Challenges in Diagnosis and Treatment
|
|
|
2010
|
|
S1 |
p. A3-A4
nvt p.
|
artikel
|
| 119 |
Peripheral T-Cell Lymphomas: Challenges in Diagnosis and Treatment
|
|
|
2010
|
|
S1 |
p. S22-
1 p.
|
artikel
|
| 120 |
Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia
|
Tonda, Raúl
|
|
2004
|
|
S1 |
p. 157-162
6 p.
|
artikel
|
| 121 |
Platelet Tissue Factor: How Did It Get There and Is It Important?
|
Key, Nigel S.
|
|
2008
|
|
S1 |
p. S16-S20
5 p.
|
artikel
|
| 122 |
Posttest
|
|
|
2007
|
|
S1 |
p. 32-
1 p.
|
artikel
|
| 123 |
Posttest
|
|
|
2010
|
|
S1 |
p. S21-
1 p.
|
artikel
|
| 124 |
Posttest
|
|
|
2009
|
|
S1 |
p. S17-S18
2 p.
|
artikel
|
| 125 |
Preface
|
Vichinsky, Elliott
|
|
2001
|
|
S1 |
p. 1-
1 p.
|
artikel
|
| 126 |
Progression of iron overload in sickle cell disease
|
Olivieri, Nancy F
|
|
2001
|
|
S1 |
p. 57-62
6 p.
|
artikel
|
| 127 |
Protein S Multimers Are Generated In Vitro and Affect Protein S Structure-Function Analyses
|
Seré, Kristin M.
|
|
2006
|
|
S1 |
p. S111-S120
10 p.
|
artikel
|
| 128 |
Recombinant Activated Factor VII in Severe Trauma
|
Riou, Bruno
|
|
2006
|
|
S1 |
p. S91-S92
2 p.
|
artikel
|
| 129 |
Recombinant Factor VIIa and COAT Platelets
|
Kjalke, Marianne
|
|
2006
|
|
S1 |
p. S122-
1 p.
|
artikel
|
| 130 |
Recombinant factor VIIa as an antidote for anticoagulant treatment
|
Levi, Marcel
|
|
2004
|
|
S1 |
p. 65-69
5 p.
|
artikel
|
| 131 |
Refractory autoimmune disease: an overview of when first-line therapy is not enough
|
Neunert, Cindy
|
|
2016
|
|
S1 |
p. S35-S38
4 p.
|
artikel
|
| 132 |
Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance
|
Siegel, David S.
|
|
2012
|
|
S1 |
p. S3-S15
13 p.
|
artikel
|
| 133 |
Resistance to Targeted Therapy in Chronic Myelogenous Leukemia
|
Hochhaus, Andreas
|
|
2007
|
|
S1 |
p. 15-24
10 p.
|
artikel
|
| 134 |
Safety profile of recombinant factor VIIa
|
Roberts, Harold R
|
|
2004
|
|
S1 |
p. 101-108
8 p.
|
artikel
|
| 135 |
Safety Update on Recombinant Factor VIIa in the Treatment of Congenital and Acquired Hemophilia
|
Abshire, Thomas
|
|
2008
|
|
S1 |
p. S3-S6
4 p.
|
artikel
|
| 136 |
Selected Topics of the 4th International Cooperative Study Group Meeting on Immune Thrombocytopenia Revisited
|
Nydegger, Urs E.
|
|
2013
|
|
S1 |
p. S3-S9
7 p.
|
artikel
|
| 137 |
Serum vitamin D levels in children with newly diagnosed and chronic immune thrombocytopenia
|
Čulić, Srđana
|
|
2016
|
|
S1 |
p. S67-S69
3 p.
|
artikel
|
| 138 |
Single-Dose Recombinant Activated Factor VII Therapy in Hemophilia Patients With Inhibitors
|
Kenet, Gili
|
|
2008
|
|
S1 |
p. S38-S41
4 p.
|
artikel
|
| 139 |
Splenectomy-sparing, long-term maintenance with anti-D for chronic immune (idiopathic) thrombocytopenic purpura: The New York hospital experience
|
Scaradavou, Andromachi
|
|
2000
|
|
S1 |
p. 42-44
3 p.
|
artikel
|
| 140 |
Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura
|
Bussel, James B
|
|
2000
|
|
S1 |
p. 1-4
4 p.
|
artikel
|
| 141 |
Standardized Clinical Assessment and Management Plans (SCAMPs): Perspectives on a New Method to Understand Treatment Decisions and Outcomes in Immune Thrombocytopenia
|
Grace, Rachael F.
|
|
2013
|
|
S1 |
p. S31-S38
8 p.
|
artikel
|
| 142 |
Status of Ongoing Collaborative Efforts
|
Vose, Julie M.
|
|
2010
|
|
S1 |
p. S18-S20
3 p.
|
artikel
|
| 143 |
Steps Towards an Effective Treatment Strategy in Congenital Factor VII Deficiency
|
Mariani, Guglielmo
|
|
2006
|
|
S1 |
p. S42-S47
6 p.
|
artikel
|
| 144 |
Strategies for minimizing blood loss in orthopedic surgery
|
Tobias, Joseph D
|
|
2004
|
|
S1 |
p. 145-156
12 p.
|
artikel
|
| 145 |
Successful Control of Central Nervous System Bleeding in Two Newborns With Severe Factor VII Deficiency Using rFVIIa Administered via Port-a-Cath
|
Karimi, Mehran
|
|
2008
|
|
S1 |
p. S74-
1 p.
|
artikel
|
| 146 |
Supplement Disclaimer
|
|
|
2008
|
|
S1 |
p. A3-
1 p.
|
artikel
|
| 147 |
Supplement Disclaimer
|
|
|
2006
|
|
S1 |
p. A4-
1 p.
|
artikel
|
| 148 |
Supplement disclaimer
|
|
|
2007
|
|
S1 |
p. A2-
1 p.
|
artikel
|
| 149 |
Supplement Disclaimer
|
|
|
2010
|
|
S1 |
p. A2-
1 p.
|
artikel
|
| 150 |
Supplement Disclaimer
|
|
|
2009
|
|
S1 |
p. A2-
1 p.
|
artikel
|
| 151 |
Supplement Sponsorship
|
|
|
2013
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 152 |
Supplement Sponsorship
|
|
|
2016
|
|
S1 |
p. A3-
1 p.
|
artikel
|
| 153 |
Supplement Sponsorship
|
|
|
2011
|
|
S1 |
p. A2-
1 p.
|
artikel
|
| 154 |
Suppl Masthead
|
|
|
2008
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 155 |
Suppl Masthead
|
|
|
2010
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 156 |
Suppl Masthead
|
|
|
2009
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 157 |
suppl masthead
|
|
|
2013
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 158 |
Suppl Masthead
|
|
|
2016
|
|
S1 |
p. IFC-
1 p.
|
artikel
|
| 159 |
Suppl TOC
|
|
|
2008
|
|
S1 |
p. A1-A2
nvt p.
|
artikel
|
| 160 |
suppl TOC
|
|
|
2013
|
|
S1 |
p. A2-A3
nvt p.
|
artikel
|
| 161 |
Surgery in Hemophilia. The General View: Patient Selection, Timing, and Preoperative Assessment
|
Ingerslev, Jørgen
|
|
2006
|
|
S1 |
p. S23-S26
4 p.
|
artikel
|
| 162 |
Table of Contents
|
|
|
2016
|
|
S1 |
p. A1-A2
nvt p.
|
artikel
|
| 163 |
Table of Contents
|
|
|
2006
|
|
S1 |
p. A1-A3
nvt p.
|
artikel
|
| 164 |
Table of Contents
|
|
|
2007
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 165 |
Table of Contents
|
|
|
2010
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 166 |
Table of Contents
|
|
|
2009
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 167 |
Table of Contents
|
|
|
2011
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 168 |
Table of Contents
|
|
|
2012
|
|
S1 |
p. A1-
1 p.
|
artikel
|
| 169 |
T cells in the pathogenesis of immune thrombocytopenia
|
Wei, Yu
|
|
2016
|
|
S1 |
p. S13-S15
3 p.
|
artikel
|
| 170 |
Techniques for blood administration in sickle cell patients
|
Eckman, James R
|
|
2001
|
|
S1 |
p. 23-29
7 p.
|
artikel
|
| 171 |
The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib Therapy
|
Alvarez, Ricardo H.
|
|
2007
|
|
S1 |
p. 4-14
11 p.
|
artikel
|
| 172 |
The Evolving Role of Bendamustine in Lymphoid Malignancy: Understanding the Drug and Its Mechanism of Action—Introduction
|
Leoni, Lorenzo M.
|
|
2011
|
|
S1 |
p. S1-S3
3 p.
|
artikel
|
| 173 |
The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies
|
Moreau, Philippe
|
|
2012
|
|
S1 |
p. S33-S46
14 p.
|
artikel
|
| 174 |
The Incidence of Factor VIII and Factor IX Inhibitors in the Hemophilia Population of the UK and Their Effect on Subsequent Mortality, 1977–99 1 *
|
Darby, Sarah C.
|
|
2006
|
|
S1 |
p. S88-
1 p.
|
artikel
|
| 175 |
The management of coagulopathy and blood loss in liver surgery
|
Silva, Michael A
|
|
2004
|
|
S1 |
p. 132-139
8 p.
|
artikel
|
| 176 |
The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients
|
|
|
2009
|
|
S1 |
p. A3-A5
nvt p.
|
artikel
|
| 177 |
The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients
|
|
|
2009
|
|
S1 |
p. S19-S20
2 p.
|
artikel
|
| 178 |
The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients
|
Young, Neal S.
|
|
2009
|
|
S1 |
p. S1-S16
16 p.
|
artikel
|
| 179 |
The nonhemostatic immune functions of platelets
|
Kapur, Rick
|
|
2016
|
|
S1 |
p. S2-S6
5 p.
|
artikel
|
| 180 |
The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura
|
McMillan, Robert
|
|
2000
|
|
S1 |
p. 5-9
5 p.
|
artikel
|
| 181 |
The Platelet: Form and Function
|
Hartwig, John H.
|
|
2006
|
|
S1 |
p. S94-S100
7 p.
|
artikel
|
| 182 |
The potential for treatment of idiopathic thrombocytopenic purpura with Anti-D to prevent splenectomy: A predictive cost analysis
|
Bennett, Charles L
|
|
2000
|
|
S1 |
p. 26-30
5 p.
|
artikel
|
| 183 |
Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase
|
Goldman, John M.
|
|
2003
|
|
S1 |
p. 10-17
8 p.
|
artikel
|
| 184 |
The spleen: Anatomy and anatomical function
|
Chadburn, Amy
|
|
2000
|
|
S1 |
p. 13-21
9 p.
|
artikel
|
| 185 |
The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura
|
Sandler, S.Gerald
|
|
2000
|
|
S1 |
p. 10-12
3 p.
|
artikel
|
| 186 |
The use of recombinant factor VIIa in head injury: a report of five cases
|
Zaaroor, Menashe
|
|
2004
|
|
S1 |
p. 175-176
2 p.
|
artikel
|
| 187 |
5th Intercontinental Cooperative ITP Study Group (ICIS) expert meeting in Flüeli-Ranft, Switzerland, September 2015
|
Imbach, Paul
|
|
2016
|
|
S1 |
p. S1-
1 p.
|
artikel
|
| 188 |
4th Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting in Montreux, Switzerland, September 2012
|
Kühne, Thomas
|
|
2013
|
|
S1 |
p. S1-S2
2 p.
|
artikel
|
| 189 |
Three Decades of Experience in Managing Immune Thrombocytopenia in Children in Arab Countries
|
Elalfy, Mohsen Saleh
|
|
2013
|
|
S1 |
p. S22-S25
4 p.
|
artikel
|
| 190 |
Thromboelastography and recombinant factor VIIa—hemophilia and beyond
|
Sørensen, B
|
|
2004
|
|
S1 |
p. 140-144
5 p.
|
artikel
|
| 191 |
Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?
|
Schifferli, Alexandra
|
|
2016
|
|
S1 |
p. S31-S34
4 p.
|
artikel
|
| 192 |
Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia
|
Siegal, Deborah
|
|
2013
|
|
S1 |
p. S18-S21
4 p.
|
artikel
|
| 193 |
Tissue factor as an evolutionary conserved cytokine receptor: implications for inflammation and signal transduction
|
Versteeg, Henri H
|
|
2004
|
|
S1 |
p. 168-172
5 p.
|
artikel
|
| 194 |
Tissue Factor–Independent Effects of Recombinant Factor VIIa on Hemostasis
|
Weeterings, Cees
|
|
2008
|
|
S1 |
p. S12-S15
4 p.
|
artikel
|
| 195 |
To Treat or Not To Treat—From Guidelines to Individualized Patient Management
|
Matzdorff, Axel
|
|
2013
|
|
S1 |
p. S12-S17
6 p.
|
artikel
|
| 196 |
Transplant decision-making strategies in the myeloproliferative disorders
|
Fruchtman, Steven M.
|
|
2003
|
|
S1 |
p. 30-33
4 p.
|
artikel
|
| 197 |
Treatment approaches in myelofibrosis with myeloid metaplasia: The old and the new
|
Tefferi, Ayalew
|
|
2003
|
|
S1 |
p. 18-21
4 p.
|
artikel
|
| 198 |
Treatment options for chronic idiopathic (immune) thrombocytopenic purpura
|
George, James N
|
|
2000
|
|
S1 |
p. 31-34
4 p.
|
artikel
|
| 199 |
Treatment options for chronic immune (idiopathic) thrombocytopenia purpura in children
|
Tarantino, Michael D
|
|
2000
|
|
S1 |
p. 35-41
7 p.
|
artikel
|
| 200 |
Ultra-early Hemostatic Therapy for Acute Intracerebral Hemorrhage
|
Mayer, Stephan A.
|
|
2006
|
|
S1 |
p. S70-S76
7 p.
|
artikel
|
| 201 |
Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis
|
Shima, Midori
|
|
2004
|
|
S1 |
p. 125-131
7 p.
|
artikel
|
| 202 |
Understanding the Importance of Using Patient-Reported Outcome Measures in Patients With Immune Thrombocytopenia
|
Kirsch, Monika
|
|
2013
|
|
S1 |
p. S39-S42
4 p.
|
artikel
|
| 203 |
Update on Liver Disease in Hemophilia Patients
|
Kessler, Craig M.
|
|
2006
|
|
S1 |
p. S13-S17
5 p.
|
artikel
|
| 204 |
Use of anti-D in immune thrombocytopenic purpura as a means to prevent splenectomy: Case reports from two university hospital medical centers
|
Waintraub, Stanley E
|
|
2000
|
|
S1 |
p. 45-49
5 p.
|
artikel
|
| 205 |
Use of the Thrombin Generation Test to Evaluate Response to Treatment With Recombinant Activated Factor VII
|
Dargaud, Yesim
|
|
2008
|
|
S1 |
p. S72-S73
2 p.
|
artikel
|
| 206 |
Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine
|
Bizjak, Mojca
|
|
2016
|
|
S1 |
p. S48-S50
3 p.
|
artikel
|
| 207 |
Variants of recombinant factor VIIa with increased intrinsic activity
|
Persson, Egon
|
|
2004
|
|
S1 |
p. 89-92
4 p.
|
artikel
|
| 208 |
Vascular biology—the role of tissue factor
|
Hathcock, James
|
|
2004
|
|
S1 |
p. 30-34
5 p.
|
artikel
|
| 209 |
Views on methods for monitoring recombinant factor VIIa in inhibitor patients
|
Key, Nigel S
|
|
2004
|
|
S1 |
p. 51-54
4 p.
|
artikel
|
| 210 |
Viruses, anti-viral therapy, and viral vaccines in children with immune thrombocytopenia
|
Elalfy, Mohsen S.
|
|
2016
|
|
S1 |
p. S70-S72
3 p.
|
artikel
|
| 211 |
What do we learn from immunomodulation in patients with immune thrombocytopenia?
|
Kuwana, Masataka
|
|
2016
|
|
S1 |
p. S27-S30
4 p.
|
artikel
|
Tijdschrift beschrijving